Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from September 13, 2025

Partial Published before the outcome was known, scored automatically when the window closed on December 12, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$54.00 – $55.00Entry zone — fair-value band

$54.87Published — price the day we called it

$64.75Target — the price the thesis aimed for

$62.32Peak — highest point inside the window, not a realized return

$50.18Window close — end-of-window price, context only

What happened

Partial

Reached 76% of the predicted growth at its peak, without hitting the target.

Peak price

$62.32

peak on September 19, 2025 — not a realized return

Peak gain

+13.6%

peak, from the publication price

Window close

$50.18

end-of-window price, context only

Days to target

—

Window

September 13, 2025 – December 12, 2025

The thesis — published September 13, 2025

Predicted growth

+18%

over the measurement window

Target price

$64.75

the price the thesis aimed for

Entry zone

$54.00 – $55.00

the fair-value band we waited for

Price at publication

$54.87

published September 13, 2025

Confidence

72%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk's stock dropped sharply on worries about patents and a reset in how the market values it. The business still leads in GLP-1 medicines, which keeps demand solid. The price looks washed out and could bounce over the next 0-3 months if buying stays steady. Trading lately suggests lots more people are buying than usual. Big risks are lawsuit headlines and pressure on U.S. pricing.

Primary drivers

Leader in GLP-1 weight-loss and diabetes drugs, keeping demand strong
Price fell hard and now shows early signs that buyers are stepping back in
Shares are cheaper after the reset, but patent fights in court are a risk
Investor interest stays high even after the recent slide and legal worries

How it played out

NVO: thesis partly played out, target missed

Lyra published NVO at $54.87 on 2025-09-13, with an 18% expected gain and a $64.75 target. The thesis pointed to leadership in GLP-1 weight-loss and diabetes drugs, a hard price reset, early signs of buyers returning, cheaper shares after the reset, and legal and U.S. pricing risks.

Inside the window, NVO rose to $62.32 on 2025-09-19, a 13.6% peak gain. It stayed below the $64.75 target. The stock ended the window at $50.18. The bounce partly matched the thesis, but the target was missed.

What happened during the window

On 2025-10-15, Investors.com reported that Novo Nordisk agreed to pay up to $2.1 billion to license Omeros's experimental rare blood and kidney disease treatment. On 2025-11-05, The Guardian reported that Novo Nordisk cut its 2025 sales and profit forecasts after third-quarter results.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals